International Research Journal of Pharmacy and Medical Sciences
ISSN (Online): 2581-3277

Review: Fibrodysplasia Ossificans Progressiva

Vankodoth Sireesha[1], Faiqua Fatima[2], Shafeen Sultana[2], Shiva Sai Kumar[2]
[1]Assistant Professor, CMR College of Pharmacy Hyderabad, Telangana
[2]Pharm D interns, CMR College of Pharmacy, Hyderabad, Telangana.

Abstract**—***Fibrodysplasia Ossificans Progressiva (FOP) is an ultra-rare genetic disorder characterized by heterotopic ossification of connective tissues and progressive loss of mobility. FOP is caused by mutations in the ACVR1 gene, leading to abnormal bone formation in muscles, tendons, and ligaments. This review explores the clinical features, genetic basis, pathophysiology, current management, and future directions for research and therapy.*

Keywords**—** *ACVR1 Gene Mutation; Bone Morphogenetic Protein (BMP) Signaling; Endochondral Ossification; Fibrodysplasia Ossificans Progressiva; Future Therapies in FOP; Genetic Disorder; Heterotopic Ossification; Inflammatory Flare-ups; Joint Ankylosis; Progressive Disability.*

I. INTRODUCTION

Fibrodysplasia Ossificans Progressiva (FOP) is an extremely rare autosomal dominant disorder with a prevalence estimated at approximately 1 in 2 million individuals worldwide. It is characterized by progressive heterotopic ossification (HO), where soft connective tissues progressively turn into bone, impairing movement and function [1]. Fibrodysplasia Ossificans Progressiva is caused by the ACVR1 gene. This change affects the body's repair process, causing tissue damage, including muscles, tendons, and ligaments, or injury. The first "tumor" that leads to bone formation in FOP occurs before age 10. Bone growth occurs from the top of the body down, just as bones grow in the womb. A child with FOP often develops extra bones in the neck, then in the shoulders, arms, chest area and finally in the legs. The hallmark features of FOP include congenital malformations of the great toes and episodic flare-ups of painful soft tissue swellings that precede the ossification.

II. CLINICAL FEATURES

The initial symptoms of FOP usually present in early childhood with episodic flare-ups that lead to the development of hard, immobile masses in soft tissues. These flare-ups often occur spontaneously or can be triggered by trauma, including minor injuries, viral illnesses, or muscle fatigue [2]. Over time, these episodes result in the progressive ossification of connective tissues, forming ribbons, sheets, and plates of bone that bridge across joints, leading to severe restriction of movement and eventual immobilization [3].

Key clinical signs include:

- Malformations of the great toes: Present at birth and can be used as a diagnostic marker.
- Heterotopic ossification: Begins in the axial skeletal muscles and progresses to appendicular muscles.
- Joint Ankylosis: Permanent fusion of joints due to ectopic bone formation.
- Progressive Disability: Patients eventually become wheelchair-bound and face challenges with breathing and eating due to chest wall and jaw ossification [1, 4].

III. GENETIC BASIS

FOP is primarily caused by a recurrent mutation in the ACVR1 gene (c.617G>A; R206H), which encodes the Activin A receptor type I, a bone morphogenetic protein (BMP) receptor. This mutation replaces codon 206 from arginine to histidine in the ACVR1 protein. This substitution results in aberrant activation of ACVR1, which leads to the conversion of connective tissue and muscle tissue into a secondary scaffold. This causes the endothelial cells to transform into MSCs and then into bone. Basically, the ACVR1 gene encodes the transmembrane type 1 activin receptor kinase that binds BMP receptors (BMPR type I and BMPR type II) for chondrocyte signaling. BMPs belong to a large family of proteins known as transforming growth factor-beta (TGF-β) proteins. ACVR1 protein binds to BMP receptors and initiates an important signaling pathway for the activation of endochondral bone formation during development, including skeletal and tissue homeostasis [2]. This pathological process leads to the formation of bone outside the normal skeletal framework, a defining feature of FOP [3].

IV. PATHOPHYSIOLOGY

The pathogenesis of FOP involves dysregulated BMP signaling, leading to the inappropriate differentiation of progenitor cells into bone-forming osteoblasts within soft connective tissues. The inflammatory microenvironment created during flare-ups is thought to play a critical role in triggering the differentiation of mesenchymal stem cells into osteoblasts, culminating in heterotopic bone formation [4]. This aberrant bone formation is exacerbated by the systemic overexpression of BMP-4 and the activated ACVR1 receptor in FOP patients [5].

V. CURRENT MANAGEMENT

Management of FOP is largely supportive and preventive, as no definitive cure or effective treatment to halt the progression of the disease currently exists. Key management strategies include:

- Avoiding trauma: Preventive measures to minimize injuries that could trigger flare-ups.

Vankodoth Sireesha, Faiqua Fatima, Shafeen Sultana, and Shiva Sai Kumar, "Review: Fibrodysplasia Ossificans Progressiva," *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 7, Issue 6, pp. 1-2, 2024.

- Medical Management: High-dose corticosteroids during flare-ups to reduce inflammation and pain. NSAIDs such as Aspirin, Ibuprofen, celecoxib, Diclofenac, fenoprofen, indomethacin, ketorolac and other analgesics such as oxycodone are used for pain management [4].
- Physical Therapy: Gentle range-of-motion exercises are encouraged, but aggressive physical therapy can exacerbate symptoms.
- Surgical Intervention: Generally avoided due to the high risk of inducing new flare-ups and subsequent ossification [1].

VI. Future Directions

Recent advances in understanding the genetic and molecular basis of FOP have opened new avenues for potential therapies. Targeted treatments aimed at inhibiting the aberrant ACVR1 receptor, blocking BMP signaling pathways, and reducing inflammation during flare-ups are currently under investigation [5]. Gene therapy, small molecule inhibitors, and immunomodulatory therapies hold promise as future therapeutic options to manage and potentially cure FOP [3, 4].

VII. Conclusion

FOP is a devastating rare genetic disorder that results in progressive disability and reduced quality of life for affected individuals. Early diagnosis, vigilant management, and ongoing research into targeted therapies are crucial for improving patient outcomes. Collaborative efforts between researchers, clinicians, and patient advocacy groups continue to be essential in advancing our understanding of FOP and developing effective treatments.

References

[1] Kaplan, F. S., Shore, E. M., & Pignolo, R. J. (2010). The FOP Metamorphogene Encodes a BMP Receptor with an Altered Function. Cytokine & Growth Factor Reviews, 21(4), 247-252.
[2] Shore, E. M., Xu, M., Feldman, G. J., Fenstermacher, D. A., Cho, T. J., Choi, I. H., ... & Kaplan, F. S. (2006). A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genetics, 38(5), 525-527.
[3] Pignolo, R. J., & Shore, E. M. (2013). Targeting BMP Signaling in Fibrodysplasia Ossificans Progressiva. Bone, 57(2), 297-302.
[4] Kaplan, F. S., Pignolo, R. J., Shore, E. M., Al Mukaddam, M. A., & Bastepe, M. (2018). Fibrodysplasia ossificans progressiva: Mechanisms, models, and therapeutic approaches. Annals of the New York Academy of Sciences, 1414(1), 119-136.
[5] Wentworth, K. L., & Hsiao, E. C. (2018). Gene Therapy and Small Molecules in FOP. Bone, 109, 248-255.

Vankodoth Sireesha, Faiqua Fatima, Shafeen Sultana, and Shiva Sai Kumar, “Review: Fibrodysplasia Ossificans Progressiva,” *International Research Journal of Pharmacy and Medical Sciences (IRJPMS)*, Volume 7, Issue 6, pp. 1-2, 2024.